Protocol Ledger

NCT03690739 · Phase III · TERMINATED

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Interventional Phase III clinical trial protocol NCT03690739 sponsored by AGO Research in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-09 Enrollment: 9 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03690739
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)9 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03690739
Protocol FieldVerified Registry Value
NCT IdentifierNCT03690739
Consolidated Lead SponsorAGO Research
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment9 participants (ACTUAL)
Registered Start Date2019-08-09
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03690739
Hospital Research SiteLocationSite Profile
Charité Universitätsmedizin BerlinBerlin, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI